Why the study?
Does CPT-I inhibition with oxfenicine prevent ventricular remodeling and delay decompensation in dogs with pacing-induced heart failure?
Population
27 dogs (9 normal, 9 untreated with pacing-induced heart failure, 9 heart failure treated with oxfenicine)
Comparison
Oxfenicine 65 mg/kg/day (a CPT-I inhibitor) vs Untreated pacing-induced heart failure dogs and…
Design
Preclinical
Follow-up
Up to terminal failure or 28 days of pacing
Authors
Loading...
Hypothesis-generating in canine pacing HF; leaves open CPT-I inhibition translation to human therapy.
Does CPT-I inhibition with oxfenicine prevent ventricular remodeling and delay decompensation in dogs with pacing-induced heart failure?
Inhibition of CPT-I with oxfenicine delays decompensation and prevents left ventricular remodeling in a canine model of pacing-induced heart failure.
Lionetti et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: